Find information on thousands of medical conditions and prescription drugs.

Valsartan

Valsartan (Diovan®) is an angiotensin II receptor antagonist, acting on the AT1 subtype. It is used to treat high blood pressure, congestive heart failure, and may be used to treat chronic renal failure.

Administration

Oral tablets, containing 40 mg, 80 mg, 160 mg or 320 mg of valsartan. Usual dosage ranges from 40-320 mg daily. Diovan HCT® contains a combination of valsartan and hydrochlorothiazide.

Side effects

Most commonly, headache and dizziness.

  • More information in PuMed for Valsartan
Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Valsartan improves survival for patients with heart failure
From Nursing, 2/1/03

* Valsartan, an angiotensin II receptor blocker, is a safe and effective alternative for patients with heart failure who can't take angiotensin-converting enzyme (ACE) inhibitors, the standard treatment, according to a recent study.

The findings were the result of a subgroup analysis of the Valsartan Heart Failure Trial, which evaluated the effects of valsartan in patients with heart failure. The subgroup analysis looked at 366 patients who weren't receiving ACE inhibitors. In these patients, morbidity and mortality were reduced when compared with the placebo group. The patients on valsartan also had physiologic improvements in ejection fraction, left ventricular internal diameter in diastole, and plasma neurohormone levels.

Source: Maggioni, A., et al. (Valsartan Heart Failure Trial Investigators): "Effects of Valsartan on Morbidity and Mortality in Patients with Heart Failure Not Receiving Angiotensin-Converting Enzyme Inhibitors," Journal of the American College of Cardiology, October 16, 2002.

Copyright Springhouse Corporation Feb 2003
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Valsartan
Home Contact Resources Exchange Links ebay